{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:34:49Z","timestamp":1789122889914,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008061","name":"Fundacion Mutua Madrile\u00f1a","doi-asserted-by":"crossref","award":["AP18051-2022"],"award-info":[{"award-number":["AP18051-2022"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22-01700"],"award-info":[{"award-number":["PI22-01700"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Artificial intelligence (AI) can predict genomic alterations from histology, yet its adoption is slowed by a lack of trust. We argue that\n                    <jats:italic>deliberate morphology<\/jats:italic>\n                    (i.e., a cognitive understanding of histological features supported by standardized annotations) creates a bidirectional feedback loop between clinical practice and model outputs.We translate these observations into an actionable hypothesis for clinical and computational teams: that by enhancing explainability, deliberate morphology could facilitate the responsible deployment of AI biomarkers in oncology.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01692-8","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:42:46Z","timestamp":1788889366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Boveri perspective on cancer biomarker testing using artificial intelligence"],"prefix":"10.1038","volume":"10","author":[{"given":"Esther","family":"Conde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Curto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lopez-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"1692_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jama.2024.0018","volume":"331","author":"AB Fogo","year":"2024","unstructured":"Fogo, A. B., Kronbichler, A. & Bajema, I. M. AI\u2019s threat to the medical profession. JAMA 331, 471\u2013472 (2024).","journal-title":"JAMA"},{"key":"1692_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMra2503232","volume":"393","author":"R-EE Abdulnour","year":"2025","unstructured":"Abdulnour, R.-E. E., Gin, B. & Boscardin, C. K. Educational strategies for clinical supervision of artificial intelligence use. N. Engl. J. Med. 393, 786\u2013797 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1692_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5858\/arpa.2023-0250-RA","volume":"149","author":"Q Gu","year":"2025","unstructured":"Gu, Q. et al. Bridging the clinical-computational transparency gap in digital pathology. Arch. Pathol. Lab. Med. 149, 276\u2013287 (2025).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1692_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104427","volume":"88","author":"MA Berb\u00eds","year":"2023","unstructured":"Berb\u00eds, M. A. et al. Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade. EBioMedicine 88, 104427 (2023).","journal-title":"EBioMedicine"},{"key":"1692_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/his.14659","volume":"80","author":"CN Heinz","year":"2022","unstructured":"Heinz, C. N., Echle, A., Foersch, S., Bychkov, A. & Kather, J. N. The future of artificial intelligence in digital pathology\u2009-\u2009results of a survey across stakeholder groups. Histopathology 80, 1121\u20131127 (2022).","journal-title":"Histopathology"},{"key":"1692_CR6","unstructured":"Boveri, T. Concerning the Origin of Malignant Tumours. (Cold Spring Harbor Laboratory Press, 2008)."},{"key":"1692_CR7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129\u20132139 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1692_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497\u20131500 (2004).","journal-title":"Science"},{"key":"1692_CR9","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao, W. et al. EGF receptor gene mutations are common in lung cancers from \u2018never smokers\u2019 and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306\u201313311 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1692_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2004.08.158","volume":"22","author":"VA Miller","year":"2004","unstructured":"Miller, V. A. et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 22, 1103\u20131109 (2004).","journal-title":"J. Clin. Oncol."},{"key":"1692_CR11","unstructured":"Sholl, L. M. et al. IASLC atlas of molecular testing for targeting therapy in lung cancer. (IASLC, Denver, 2023)."},{"key":"1692_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/path.2892","volume":"224","author":"HA Al-Ahmadie","year":"2011","unstructured":"Al-Ahmadie, H. A. et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J. Pathol. 224, 270\u2013279 (2011).","journal-title":"J. Pathol."},{"key":"1692_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/modpathol.2016.198","volume":"30","author":"J Shia","year":"2017","unstructured":"Shia, J. et al. Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. Mod. Pathol. 30, 599\u2013609 (2017).","journal-title":"Mod. Pathol."},{"key":"1692_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050120","volume":"5","author":"A Viros","year":"2008","unstructured":"Viros, A. et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5, e120 (2008).","journal-title":"PLoS Med"},{"key":"1692_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00428-024-03761-4","volume":"484","author":"C Kim","year":"2024","unstructured":"Kim, C. et al. Differentiating BRAF V600E- and RAS-like alterations in encapsulated follicular patterned tumors through histologic features: a validation study. Virchows Arch. 484, 645\u2013656 (2024).","journal-title":"Virchows Arch."},{"key":"1692_CR16","doi-asserted-by":"publisher","first-page":"100146","DOI":"10.1016\/j.modpat.2023.100146","volume":"36","author":"R Mehra","year":"2023","unstructured":"Mehra, R. et al. Highly recurrent IDH1 mutations in prostate cancer with psammomatous calcification. Mod. Pathol. 36, 100146 (2023).","journal-title":"Mod. Pathol."},{"key":"1692_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han, G. et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat. Commun. 12, 5606 (2021).","journal-title":"Nat. Commun."},{"key":"1692_CR18","doi-asserted-by":"publisher","first-page":"100965","DOI":"10.1016\/j.modpat.2026.100965","volume":"39","author":"CA Febres-Aldana","year":"2026","unstructured":"Febres-Aldana, C. A. et al. Pulmonary solid and granular adenocarcinomas expressing HepPar1\/CPS1: highly aggressive tumors exhibiting mitochondrial adaptation to STK11 mutations rather than hepatoid differentiation. Mod. Pathol. 39, 100965 (2026).","journal-title":"Mod. Pathol."},{"key":"1692_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.5858\/arpa.2024-0081-OA","volume":"149","author":"A Kime","year":"2025","unstructured":"Kime, A. et al. Can morphology and immune infiltration predict the homologous recombination deficiency status in newly diagnosed high-grade serous ovarian carcinoma?: Lessons from the PAOLA-1\/ENGOT-ov25 trial, a GINECO study. Arch. Pathol. Lab. Med. 149, 741\u2013750 (2025).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1692_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/PAS.0000000000002165","volume":"48","author":"K Keyhanian","year":"2024","unstructured":"Keyhanian, K., Han, L., Howitt, B. E. & Longacre, T. Specific pathology features enrich selection of endometrial carcinomas for POLE testing. Am. J. Surg. Pathol. 48, 292\u2013301 (2024).","journal-title":"Am. J. Surg. Pathol."},{"key":"1692_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","volume":"52","author":"I Cort\u00e9s-Ciriano","year":"2020","unstructured":"Cort\u00e9s-Ciriano, I. et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat. Genet. 52, 331\u2013341 (2020).","journal-title":"Nat. Genet."},{"key":"1692_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.tips.2024.01.009","volume":"45","author":"S Bhatia","year":"2024","unstructured":"Bhatia, S., Khanna, K. K. & Duijf, P. H. G. Targeting chromosomal instability and aneuploidy in cancer. Trends Pharmacol. Sci. 45, 210\u2013224 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"1692_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.5858\/arpa.2020-0400-RA","volume":"145","author":"E Conde","year":"2021","unstructured":"Conde, E. et al. Pan-TRK immunohistochemistry: an example-based practical approach to efficiently identify patients with NTRK fusion cancer. Arch. Pathol. Lab. Med. 145, 1031\u20131040 (2021).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1692_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0002-9440(10)61684-7","volume":"159","author":"P Argani","year":"2001","unstructured":"Argani, P. et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am. J. Pathol. 159, 179\u2013192 (2001).","journal-title":"Am. J. Pathol."},{"key":"1692_CR25","unstructured":"Chabris, C. & Simons, D. The Invisible Gorilla and Other Ways Our Intuitions Deceive Us. (HarperCollins, 2011)."},{"key":"1692_CR26","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.annonc.2025.03.006","volume":"36","author":"A Marra","year":"2025","unstructured":"Marra, A. et al. Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives. Ann. Oncol. 36, 712\u2013725 (2025).","journal-title":"Ann. Oncol."},{"key":"1692_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.landig.2025.100891","volume":"7","author":"M Gustav","year":"2025","unstructured":"Gustav, M. et al. Assessing genotype-phenotype correlations in colorectal cancer with deep learning: a multicentre cohort study. Lancet Digit. Health 7, 100891 (2025).","journal-title":"Lancet Digit. Health"},{"key":"1692_CR28","doi-asserted-by":"publisher","unstructured":"Neidlinger, P. et al. Benchmarking foundation models as feature extractors for weakly supervised computational pathology. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-025-01516-3 (2025).","DOI":"10.1038\/s41551-025-01516-3"},{"key":"1692_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1470-2045(24)00599-0","volume":"26","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study. Lancet Oncol. 26, 136\u2013146 (2025).","journal-title":"Lancet Oncol."},{"key":"1692_CR30","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jid.2021.09.034","volume":"142","author":"RH Kim","year":"2022","unstructured":"Kim, R. H. et al. Deep learning and pathomics analyses reveal cell nuclei as important features for mutation prediction of BRAF-mutated melanomas. J. Invest. Dermatol. 142, 1650\u20131658.e6 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"1692_CR31","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1158\/1078-0432.CCR-21-4391","volume":"28","author":"S Fujii","year":"2022","unstructured":"Fujii, S. et al. Rapid screening using pathomorphologic interpretation to detect BRAFV600E mutation and microsatellite instability in colorectal cancer. Clin. Cancer Res. 28, 2623\u20132632 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1692_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00623-9","volume":"8","author":"J Abel","year":"2024","unstructured":"Abel, J. et al. AI powered quantification of nuclear morphology in cancers enables prediction of genome instability and prognosis. npj Precis. Oncol. 8, 134 (2024).","journal-title":"npj Precis. Oncol."},{"key":"1692_CR33","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/s41591-025-03780-x","volume":"31","author":"G Campanella","year":"2025","unstructured":"Campanella, G. et al. Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection. Nat. Med. 31, 3002\u20133010 (2025).","journal-title":"Nat. Med."},{"key":"1692_CR34","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s43018-020-0085-8","volume":"1","author":"Y Fu","year":"2020","unstructured":"Fu, Y. et al. Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis. Nat. Cancer 1, 800\u2013810 (2020).","journal-title":"Nat. Cancer"},{"key":"1692_CR35","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1038\/s41591-024-03141-0","volume":"30","author":"E Vorontsov","year":"2024","unstructured":"Vorontsov, E. et al. A foundation model for clinical-grade computational pathology and rare cancers detection. Nat. Med. 30, 2924\u20132935 (2024).","journal-title":"Nat. Med."},{"key":"1692_CR36","doi-asserted-by":"publisher","unstructured":"Boehm, K. M. et al. Integrated histopathologic modeling of detailed tumor subtypes and actionable biomarkers. bioRxiv 2025.08.14.670351 https:\/\/doi.org\/10.1101\/2025.08.14.670351 (2025).","DOI":"10.1101\/2025.08.14.670351"},{"key":"1692_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s43018-020-0087-6","volume":"1","author":"JN Kather","year":"2020","unstructured":"Kather, J. N. et al. Pan-cancer image-based detection of clinically actionable genetic alterations. Nat. Cancer 1, 789\u2013799 (2020).","journal-title":"Nat. Cancer"},{"key":"1692_CR38","doi-asserted-by":"publisher","first-page":"100980","DOI":"10.1016\/j.xcrm.2023.100980","volume":"4","author":"JM Niehues","year":"2023","unstructured":"Niehues, J. M. et al. Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: a retrospective multi-centric study. Cell Rep. Med. 4, 100980 (2023).","journal-title":"Cell Rep. Med."},{"key":"1692_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/jcp-2024-209910","volume":"78","author":"S Hacking","year":"2025","unstructured":"Hacking, S. Foundation models in pathology: bridging AI innovation and clinical practice. J. Clin. Pathol. 78, 433\u2013435 (2025).","journal-title":"J. Clin. Pathol."},{"key":"1692_CR40","doi-asserted-by":"publisher","first-page":"113467","DOI":"10.1016\/j.ejca.2023.113467","volume":"197","author":"M Aldea","year":"2024","unstructured":"Aldea, M., Ghigna, M. R., Lacroix-Triki, M. & Andre, F. Unlocking the potential of AI-assisted pathology for molecular alteration screening. Eur. J. Cancer 197, 113467 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1692_CR41","doi-asserted-by":"publisher","first-page":"e2514460","DOI":"10.1001\/jamanetworkopen.2025.14460","volume":"8","author":"MF Griot","year":"2025","unstructured":"Griot, M. F. & Walker, G. A. A patient-in-the-loop approach to artificial intelligence in medicine. JAMA Netw. Open 8, e2514460 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1692_CR42","doi-asserted-by":"publisher","first-page":"100439","DOI":"10.1016\/j.modpat.2024.100439","volume":"37","author":"K Elfer","year":"2024","unstructured":"Elfer, K. et al. Reproducible reporting of the collection and evaluation of annotations for artificial intelligence models. Mod. Pathol. 37, 100439 (2024).","journal-title":"Mod. Pathol."},{"key":"1692_CR43","doi-asserted-by":"publisher","first-page":"102203","DOI":"10.1016\/j.labinv.2024.102203","volume":"105","author":"D Montezuma","year":"2025","unstructured":"Montezuma, D. et al. Annotation practices in computational pathology: a European Society of Digital and Integrative Pathology (ESDIP) Survey Study. Lab. Invest. 105, 102203 (2025).","journal-title":"Lab. Invest."},{"key":"1692_CR44","doi-asserted-by":"publisher","first-page":"100086","DOI":"10.1016\/j.modpat.2022.100086","volume":"36","author":"D Montezuma","year":"2023","unstructured":"Montezuma, D. et al. Annotating for artificial intelligence applications in digital pathology: a practical guide for pathologists and researchers. Mod. Pathol. 36, 100086 (2023).","journal-title":"Mod. Pathol."},{"key":"1692_CR45","doi-asserted-by":"crossref","unstructured":"Loaiza-Bonilla, A. & Penberthy, S. Harnessing Moravec\u2019s paradox in health care: a new era of collaborative intelligence. NEJM AI 2, (2025).","DOI":"10.1056\/AIp2500005"},{"key":"1692_CR46","unstructured":"Minsky, M. The Society of Mind. (Simon & Schuster, New York, 1986)."},{"key":"1692_CR47","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1016\/S2589-7500(24)00095-5","volume":"6","author":"L Tikhomirov","year":"2024","unstructured":"Tikhomirov, L. et al. Medical artificial intelligence for clinicians: the lost cognitive perspective. Lancet Digit. Health 6, e589\u2013e594 (2024).","journal-title":"Lancet Digit. Health"},{"key":"1692_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41571-025-01108-9","volume":"23","author":"MS Patel","year":"2026","unstructured":"Patel, M. S., Dee, E. C. & Lee, N. Y. AI and human expertise in cancer care - striving for synergy. Nat. Rev. Clin. Oncol. 23, 87\u201388 (2026).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1692_CR49","doi-asserted-by":"publisher","first-page":"100932","DOI":"10.1016\/j.modpat.2025.100932","volume":"39","author":"E Baumann","year":"2026","unstructured":"Baumann, E. et al. MSAI-path: predicting microsatellite instability from routine histology slides without reinventing the wheel. Mod. Pathol. 39, 100932 (2026).","journal-title":"Mod. Pathol."},{"key":"1692_CR50","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-100048","volume":"45","author":"A Loaiza-Bonilla","year":"2025","unstructured":"Loaiza-Bonilla, A. et al. Driving knowledge to action: building a better future with artificial intelligence-enabled multidisciplinary oncology. Am. Soc. Clin. Oncol. Educ. Book 45, e100048 (2025).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1692_CR51","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.jtho.2025.07.009","volume":"20","author":"M Aldea","year":"2025","unstructured":"Aldea, M. et al. Molecular tumor boards: a consensus statement from the International Association for the Study of Lung Cancer. J. Thorac. Oncol. 20, 1594\u20131614 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"1692_CR52","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jama.2022.3580","volume":"327","author":"CA James","year":"2022","unstructured":"James, C. A., Wachter, R. M. & Woolliscroft, J. O. Preparing clinicians for a clinical world influenced by artificial intelligence. JAMA 327, 1333\u20131334 (2022).","journal-title":"JAMA"},{"key":"1692_CR53","doi-asserted-by":"publisher","unstructured":"Aldea, M. et al. ESMO basic requirements for AI-based biomarkers in oncology (EBAI). Ann. Oncol. S0923-7534 06267\u20132 https:\/\/doi.org\/10.1016\/j.annonc.2025.11.009 (2025).","DOI":"10.1016\/j.annonc.2025.11.009"},{"key":"1692_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.landig.2025.100933","volume":"7","author":"LA Shaktah","year":"2025","unstructured":"Shaktah, L. A. et al. Application of artificial intelligence and digital tools in cancer pathology. Lancet Digit. Health 7, 100933 (2025).","journal-title":"Lancet Digit. Health"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01692-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:46:04Z","timestamp":1789119964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01692-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1692"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01692-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.C. and S.H. have received honoraria from AstraZeneca and Roche. M.A. reports honoraria from Roche. F.L.-R. serves as Chair of the International Association for the Study of Lung Cancer (IASLC) Pathology Committee and declares honoraria from AstraZeneca, AbbVie, BMS, Janssen, Daiichi Sankyo, Lilly, MSD, Pfizer, Roche, and Thermo Fisher. E.C., S.H. and F.L.-R. have received institutional research grants from AstraZeneca, Lilly, Roche and Thermo Fisher. D.C. reports no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"350"}}